BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 29679756)

  • 1. MYH9: Structure, functions and role of non-muscle myosin IIA in human disease.
    Pecci A; Ma X; Savoia A; Adelstein RS
    Gene; 2018 Jul; 664():152-167. PubMed ID: 29679756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease.
    Marini M; Bruschi M; Pecci A; Romagnoli R; Musante L; Candiano G; Ghiggeri GM; Balduini C; Seri M; Ravazzolo R
    Int J Mol Med; 2006 May; 17(5):729-36. PubMed ID: 16596254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease.
    Pecci A; Panza E; Pujol-Moix N; Klersy C; Di Bari F; Bozzi V; Gresele P; Lethagen S; Fabris F; Dufour C; Granata A; Doubek M; Pecoraro C; Koivisto PA; Heller PG; Iolascon A; Alvisi P; Schwabe D; De Candia E; Rocca B; Russo U; Ramenghi U; Noris P; Seri M; Balduini CL; Savoia A
    Hum Mutat; 2008 Mar; 29(3):409-17. PubMed ID: 18059020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linking the Landscape of
    Asensio-Juárez G; Llorente-González C; Vicente-Manzanares M
    Cells; 2020 Jun; 9(6):. PubMed ID: 32545517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets.
    Pertuy F; Eckly A; Weber J; Proamer F; Rinckel JY; Lanza F; Gachet C; Léon C
    Blood; 2014 Feb; 123(8):1261-9. PubMed ID: 24243973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloning of the murine non-muscle myosin heavy chain IIA gene ortholog of human MYH9 responsible for May-Hegglin, Sebastian, Fechtner, and Epstein syndromes.
    D'Apolito M; Guarnieri V; Boncristiano M; Zelante L; Savoia A
    Gene; 2002 Mar; 286(2):215-22. PubMed ID: 11943476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYH9-Related Thrombocytopenia: Four Novel Variants Affecting the Tail Domain of the Non-Muscle Myosin Heavy Chain IIA Associated with a Mild Clinical Evolution of the Disorder.
    Zaninetti C; De Rocco D; Giangregorio T; Bozzi V; Demeter J; Leoni P; Noris P; Ryhänen S; Barozzi S; Pecci A; Savoia A
    Hamostaseologie; 2019 Feb; 39(1):87-94. PubMed ID: 29996171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity.
    Sanborn KB; Mace EM; Rak GD; Difeo A; Martignetti JA; Pecci A; Bussel JB; Favier R; Orange JS
    Blood; 2011 Nov; 118(22):5862-71. PubMed ID: 22123909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
    Verver EJ; Topsakal V; Kunst HP; Huygen PL; Heller PG; Pujol-Moix N; Savoia A; Benazzo M; Fierro T; Grolman W; Gresele P; Pecci A
    Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R705H mutation of MYH9 is associated with MYH9-related disease and not only with non-syndromic deafness DFNA17.
    Verver E; Pecci A; De Rocco D; Ryhänen S; Barozzi S; Kunst H; Topsakal V; Savoia A
    Clin Genet; 2015 Jul; 88(1):85-9. PubMed ID: 24890873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Of mice and men: Relevance of cellular and molecular characterizations of myosin IIA to MYH9-related human disease.
    Even-Ram S; Yamada KM
    Cell Adh Migr; 2007; 1(3):152-5. PubMed ID: 19262128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells.
    Pecci A; Bozzi V; Panza E; Barozzi S; Gruppi C; Seri M; Balduini CL
    Thromb Haemost; 2011 Oct; 106(4):693-704. PubMed ID: 21833445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations.
    Pecci A; Klersy C; Gresele P; Lee KJ; De Rocco D; Bozzi V; Russo G; Heller PG; Loffredo G; Ballmaier M; Fabris F; Beggiato E; Kahr WH; Pujol-Moix N; Platokouki H; Van Geet C; Noris P; Yerram P; Hermans C; Gerber B; Economou M; De Groot M; Zieger B; De Candia E; Fraticelli V; Kersseboom R; Piccoli GB; Zimmermann S; Fierro T; Glembotsky AC; Vianello F; Zaninetti C; Nicchia E; Güthner C; Baronci C; Seri M; Knight PJ; Balduini CL; Savoia A
    Hum Mutat; 2014 Feb; 35(2):236-47. PubMed ID: 24186861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
    Heath KE; Campos-Barros A; Toren A; Rozenfeld-Granot G; Carlsson LE; Savige J; Denison JC; Gregory MC; White JG; Barker DF; Greinacher A; Epstein CJ; Glucksman MJ; Martignetti JA
    Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease.
    Pal K; Nowak R; Billington N; Liu R; Ghosh A; Sellers JR; Fowler VM
    Blood; 2020 May; 135(21):1887-1898. PubMed ID: 32315395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered cytoskeleton organization in platelets from patients with MYH9-related disease.
    Canobbio I; Noris P; Pecci A; Balduini A; Balduini CL; Torti M
    J Thromb Haemost; 2005 May; 3(5):1026-35. PubMed ID: 15869600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of mouse model of MYH9 disorders: heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability.
    Suzuki N; Kunishima S; Ikejiri M; Maruyama S; Sone M; Takagi A; Ikawa M; Okabe M; Kojima T; Saito H; Naoe T; Matsushita T
    PLoS One; 2013; 8(8):e71187. PubMed ID: 23976996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes.
    Arrondel C; Vodovar N; Knebelmann B; Grünfeld JP; Gubler MC; Antignac C; Heidet L
    J Am Soc Nephrol; 2002 Jan; 13(1):65-74. PubMed ID: 11752022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYH9-siRNA and MYH9 mutant alleles: expression in cultured cell lines and their effects upon cell structure and function.
    Li Y; Friedmann DR; Mhatre AN; Lalwani AK
    Cell Motil Cytoskeleton; 2008 May; 65(5):393-405. PubMed ID: 18330899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late onset and high-frequency dominant hearing loss in a family with MYH9 disorder.
    Wasano K; Matsunaga T; Ogawa K; Kunishima S
    Eur Arch Otorhinolaryngol; 2016 Nov; 273(11):3547-3552. PubMed ID: 26942920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.